Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call Transcript

Feb 04, 2025 / 01:30PM GMT

Release Date Price: $701.18 (+5.31%)

Transcript 10-K8-K

Key Points

Positve

Regeneron Pharmaceuticals Inc (REGN) reported a strong fourth quarter with 10% revenue growth, driven by key franchises like Dupixent, Libtayo, and EYLEA.
The company has a robust pipeline with approximately 40 product candidates across various therapeutic areas, showcasing significant future potential.
Dupixent continues to be a transformative medicine with over 1 million patients worldwide and is well-positioned for future growth with new indications.
Regeneron Pharmaceuticals Inc (REGN) announced the initiation of a quarterly cash dividend program and an additional $3 billion share repurchase authorization, reflecting confidence in future cash flows.
The company is advancing several promising R&D programs, including pivotal data expected for Linvoseltamab in multiple myeloma and odronextamab in follicular lymphoma.

Negative

Regeneron Pharmaceuticals Inc (REGN) faces ongoing competitive pressure in the anti-VEGF category, particularly affecting EYLEA sales.
The company anticipates continued market dynamics that may put downward pressure on EYLEA business due to biosimilar competition.
There are concerns about the safety profile of some pipeline products, such as the complement programs, which have shown class-specific adverse events.
The company expects increased operating expenses in 2025, driven by costs to support the expanding late-stage pipeline and international expansion.
Regeneron Pharmaceuticals Inc (REGN) does not provide specific guidance on sales erosion expectations for the EYLEA franchise, leaving some uncertainty for investors.

Operator

Hello, and welcome to Regeneron Pharmaceuticals' fourth quarter 2024 earnings conference call. My name is Tawanda, and I will be your operator for today's call. (Operator Instructions) Please note that this conference is being recorded.

I will now turn the call over to Ryan Crow, Senior Vice President, Investor Relations.

Ryan Crowe

Regeneron Pharmaceuticals Inc - Senior Vice President of IR & Strategic Analysis

Thank you, Tawanda. Good morning, good afternoon, and good evening to everyone listening around the world. Thank you for your interest in Regeneron , and welcome to our fourth quarter 2024 earnings conference call. An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after the call ends.

Joining me on today's call are Dr. Leonard Schleifer, Board Co-Chair, Co-Founder, President, and Chief Executive Officer; Dr. George Yancopoulos, Board Co-Chair, Co-Founder, President, and Chief Scientific Officer; Marion McCourt, Executive Vice President of Commercial; and Chris Fenimore,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.